Since May 2018, the Munich leukemia laboratory has been featuring its very own conference facility covering an area of 500 sqm. It has a bright and spacious foyer, providing a space for receptions and events of all kinds. From the front of the foyer you can access the “large training room”, which can accommodate 190 people and is equipped with a 6.70m x 1.71m LED wall, several cameras as well as an integrated sound and loudspeaker system, making it one of the largest video conference rooms in Germany.

Approx. 10% of all hematological neoplasias are plasma cell diseases such as multiple myeloma (MM) or plasma cell leukemias. As is the case for other hematological diseases, molecular genetic diagnostics can be viewed as increasingly relevant in the diagnosis, prognosis and therapeutic stratification of MM. This is especially true given that MM in genetic terms is a highly heterogeneous neoplasia. MLL currently offers a molecular genetic panel that includes the BRAF, KRAS, NRAS and TP53 genes.

Making a patient disease diagnosis on the basis of Next-Generation Sequencing (NGS) data is a complex endeavor. To be able to make an exact diagnosis, medical professionals must be able to access all the available information pertaining to the specific genetic variants detected. This is not only time-consuming, but also requires extensive investment. This is further complicated by the fact that not all genetic variants have been described or precisely annotated. The annotation itself is sometimes not easily accessed or may be ambiguous from one source to another.

Next-generation sequencing (NGS) has rapidly become an indispensable tool in diagnostic molecular genetics. A recent article in Blood (Steensma Blood 2018) examined how patients with ambiguous cytopenia or with a (suspected) MDS diagnosis can benefit from the diagnostic potential of NGS. For this reason, MLL Münchner Leukämielabor has taken a closer look at the importance of extended molecular diagnostics for (suspected) MDS, with particular emphasis given to cases in which MDS cannot be confirmed using conventional methods. Currently, NGS already plays an important role in the diagnosis of AML and it is expected to play even more significant role in the future. Our next newsletter (2/2019) will therefore focus on the central role of comprehensive molecular diagnostics in (suspected) cases of AML.

In order to be optimally equipped for the future, MLL Münchner Leukämielabor founded the affiliate company MLLi ("i" here stands for "innovation") on 08/31/2017 to focus on technological specialization. Because innovation is increasingly focusing on software, the newly established company will be dedicated to the digital processing of data from leukemia diagnostics. Among other things, MLLi will provide scientists, researchers, doctors, and biologists with browser-based tools for the interpretation of molecular, cytogenetic and immunophenotype data for hematological diagnoses.